A new tumorgraft panel to accelerate precision medicine in prostate cancer.

ABSTRACT:

Background

Despite the significant advances in the management of advanced prostate cancer (PCa), metastatic PCa is currently considered incurable. For further investigations in precision treatment, the development of preclinical models representing the complex prostate tumor heterogeneity are mandatory. Accordingly, we aimed to establish a resource of patient-derived xenograft (PDX) models that exemplify each phase of this multistage disease for accurate and rapid evaluation of candidate therapies.

Methods

Fresh tumor samples along with normal corresponding tissues were obtained directly from patients at surgery. To ensure that the established models reproduce the main features of patient's tumor, both PDX tumors at multiple passages and patient's primary tumors, were proces

SUBMITTER: Beraud C 

PROVIDER: S-EPMC10250751 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature